If you have any questions for next week's webinar guest speakers (Pyx Resources, Helix Exploration, Fulcrum Metals and Metals One), please submit them here.

Less Ads, More Data, More Tools Register for FREE

GSK asks to appeal Delaware ruling allowing Zantac cases to go forward

Tue, 11th Jun 2024 00:32

June 10 (Reuters) -

GSK and other drugmakers on Monday asked a Delaware court for permission to appeal a

ruling allowing more than 70,000 lawsuits claiming that heartburn drug Zantac causes cancer to go forward.

If Judge Vivian Medinilla of Delaware Superior Court grants

the petition

, which is also joined by Pfizer, Sanofi and Boehringer Ingelheim, the appeal will go directly to the Delaware Supreme Court. If she denies it, GSK said, the companies will ask the Supreme Court directly to hear the case.

The companies, which all sold Zantac at different times, argue that Medinilla should have granted their motion to block plaintiffs from presenting expert testimony that Zantac causes cancer. That would have effectively ended all of the lawsuits in Delaware, where the vast majority of Zantac lawsuits nationwide are pending.

Also on Monday, GSK announced that a woman who alleged that she developed breast cancer as a result of taking Zantac dropped her case shortly before it was set for trial.

GSK said in a statement that it did not settle with the woman, Eugenia Kasza. A lawyer for Kasza did not immediately respond to a request for comment.

Kasza's case would have been the second over Zantac to go to trial, after the first ended last month with a victory for GSK and Boehringer Ingelheim. Another case was dismissed by a judge shortly before a trial was set to begin on May 23.

Sanofi has settled about 4,000 Zantac cases, and the Financial Times reported last month that Pfizer had settled more than 10,000 cases.

First approved in 1983, Zantac became the world's best-selling medicine in 1988 and one of the first to top $1 billion in annual sales. It was originally marketed by a forerunner of GSK and later sold successively to other companies.

In 2019, some manufacturers and pharmacies halted Zantac sales after a chemical called NDMA, which is known to cause cancer, was detected in some pills. Some tests showed that Zantac's active ingredient, ranitidine, could degrade into NDMA over time or when exposed to heat.

The U.S. Food and Drug Administration asked manufacturers to pull the drug off the market in 2020. In the face of mounting lawsuits, the drugmakers have maintained that there is no evidence Zantac exposed users to harmful levels of NDMA.

The companies notched a significant win in 2022, when another judge rejected about 50,000 lawsuits making similar claims that had been consolidated in federal court in Florida. Some plaintiffs are appealing that ruling. (Reporting vy Brendan Pierson in New York; Editing by Alexia Garamfalvi, Bill Berkrot and Leslie Adler))

Related Shares

More News
19 Jul 2024 17:08

London close: Stocks fall on day of global IT chaos

(Sharecast News) - London's stock markets closed in the red on Friday, affected by a significant global IT outage and a drop in UK retail sales.

19 Jul 2024 12:33

GSK application for myeloma treatment accepted by EMA

(Sharecast News) - GSK announced on Friday that the European Medicines Agency (EMA) has accepted its marketing authorisation application for 'Blenrep'...

19 Jul 2024 08:57

LONDON MARKET OPEN: Stocks suffer on underwhelming local data

(Alliance News) - The FTSE 100 opened higher in London on Friday morning, while other stocks remained downbeat, as a nationwide tech outage combined w...

19 Jul 2024 08:12

GSK drug for multiple myeloma accepted for European regulatory review

(Alliance News) - GSK PLC on Friday said its treatment for relapsed or refractory multiple myeloma has been accepted for review by a European regulato...

15 Jul 2024 14:26

Second malaria vaccine launched in Ivory Coast in new milestone

LONDON, July 15 (Reuters) - The world's second vaccine against malaria was launched on Monday as Ivory Coast began a routine vaccine programme using...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.